Viridian Therapeutics VRDN Stock
Viridian Therapeutics Price Chart
Viridian Therapeutics VRDN Financial and Trading Overview
| Viridian Therapeutics stock price | 24.29 USD |
| Previous Close | 24.5 USD |
| Open | 24.65 USD |
| Bid | 17.62 USD x 200 |
| Ask | 31.15 USD x 200 |
| Day's Range | 24.07 - 24.74 USD |
| 52 Week Range | 13.18 - 34.29 USD |
| Volume | 893.83K USD |
| Avg. Volume | 2M USD |
| Market Cap | 2.75B USD |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.63 USD |
VRDN Valuation Measures
| Enterprise Value | 2.11B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.75994 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 38.689518 |
| Price/Book (mrq) | 4.9379954 |
| Enterprise Value/Revenue | 29.709 |
| Enterprise Value/EBITDA | -5.221 |
Trading Information
Viridian Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.94 |
| 52-Week Change | 27.43% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 34.29 USD |
| 52 Week Low | 13.18 USD |
| 50-Day Moving Average | 19.58 USD |
| 200-Day Moving Average | 23.97 USD |
VRDN Share Statistics
| Avg. Volume (3 month) | 2M USD |
| Avg. Daily Volume (10-Days) | 1.82M USD |
| Shares Outstanding | 113.29M |
| Float | 106.47M |
| Short Ratio | 10.14 |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 123.28% |
| Shares Short | 19.23M |
| Short % of Float | 17.59% |
| Short % of Shares Outstanding | 16.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -44460.56% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.15% |
| Return on Equity (ttm) | -65.74% |
Income Statement
| Revenue (ttm) | 71.13M USD |
| Revenue Per Share (ttm) | 0.74 USD |
| Quarterly Revenue Growth (yoy) | 278.69% |
| Gross Profit (ttm) | -253548992 USD |
| EBITDA | -404731008 USD |
| Net Income Avi to Common (ttm) | -334032000 USD |
| Diluted EPS (ttm) | -3.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 981.53M USD |
| Total Cash Per Share (mrq) | 8.66 USD |
| Total Debt (mrq) | 244.73M USD |
| Total Debt/Equity (mrq) | 36.96 USD |
| Current Ratio (mrq) | 16.949 |
| Book Value Per Share (mrq) | 4.919 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -333343008 USD |
| Levered Free Cash Flow (ttm) | -275496000 USD |
Profile of Viridian Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 221 Crescent Street |
| ZIP | 02453 |
| Phone | 617 272 4600 |
| Website | https://www.viridiantherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 252 |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Q&A For Viridian Therapeutics Stock
What is a current VRDN stock price?
Viridian Therapeutics VRDN stock price today per share is 24.29 USD.
How to purchase Viridian Therapeutics stock?
You can buy VRDN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viridian Therapeutics?
The stock symbol or ticker of Viridian Therapeutics is VRDN.
Which industry does the Viridian Therapeutics company belong to?
The Viridian Therapeutics industry is Biotechnology.
How many shares does Viridian Therapeutics have in circulation?
The max supply of Viridian Therapeutics shares is 113.29M.
What is Viridian Therapeutics Price to Earnings Ratio (PE Ratio)?
Viridian Therapeutics PE Ratio is now.
What was Viridian Therapeutics earnings per share over the trailing 12 months (TTM)?
Viridian Therapeutics EPS is -3.4 USD over the trailing 12 months.
Which sector does the Viridian Therapeutics company belong to?
The Viridian Therapeutics sector is Healthcare.
Viridian Therapeutics VRDN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3212.16 USD — |
+0.87
|
— — | 3191.61 USD — | 3213.52 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4033.9 USD — |
+0.7
|
— — | 4010.38 USD — | 4037.39 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
- {{ link.label }} {{link}}
